Yanling Liao

Yanling Liao

Auto-generated profile, based on publicly available information

Yanling Liao

Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XCXiaohui Chen
Xiaohui Chen
DCDongtai Chen
Dongtai Chen
QLQiang Li
Qiang Li
SWShuyan Wu
Shuyan Wu
JPJiahao Pan
Jiahao Pan
WZWeian Zeng
Weian Zeng
Background. Perinatal hypoxia is a universal cause of death and neurological deficits in neonates worldwide. Activation of microglial NADPH oxidase 2 (NOX2) leads to oxidative stress and neuroinflammation, which may contribute to hypoxic damage in the developing brain. Dexmedetomidine has been reported to exert potent neuroprotection in several neurological diseases, but the mechanism remains unclear. We investigated whether dexmedetomidine acts through microglial NOX2 to reduce neonatal hypoxic brain damage. Methods. The potential role of microglial NOX2 in dexmedetomidine‐mediated alleviation of hypoxic damage was evaluated in cultured BV2 microglia and neonatal rats subjected to hypoxia. In vivo, neonatal rats received dexmedetomidine (25 μg/kg, i.p.) 30 min before or immediately after hypoxia (5% O2, 2 h). Apocynin‐mediated NOX inhibition and lentivirus‐mediated NOX2 overexpression were applied to further assess the involvement of microglial NOX2 activation. Results. Pre‐ or posttreatment with dexmedetomidine alleviated hypoxia‐induced cognitive impairment, restored damaged synapses, and increased postsynaptic density‐95 and synaptophysin protein expression following neonatal hypoxia. Importantly, dexmedetomidine treatment suppressed hypoxia‐induced microglial NOX2 activation and subsequent oxidative stress and the neuroinflammatory response, as reflected by reduced 4‐hydroxynonenal and ROS accumulation, and decreased nuclear NF‐κB p65 and proinflammatory cytokine levels in cultured BV2 microglia and the developing hippocampus. In addition, treating primary hippocampal neurons with conditioned medium (CM) from hypoxia‐activated BV2 microglia resulted in neuronal damage, which was alleviated by CM from dexmedetomidine‐treated microglia. Moreover, the neuroprotective effect of dexmedetomidine was reversed in NOX2‐overexpressing BV2 microglia and diminished in apocynin‐pretreated neonatal rats. Conclusion. Dexmedetomidine targets microglial NOX2 to reduce oxidative stress and neuroinflammation and subsequently protects against hippocampal synaptic loss following neonatal hypoxia.

1 October 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YLYanling Liao
Yanling Liao
SXSiyu Xie
Siyu Xie
YZYifen Zhuo
Yifen Zhuo
SCSisi Chen
Sisi Chen
YLYuxin Luo
Yuxin Luo
YYYusheng Yao
Yusheng Yao
Purpose: Emergence delirium and postoperative negative behavioral changes (PNBC) are common complications in pediatric anesthesia. This study evaluated whether intranasal premedication combining dexmedetomidine and esketamine more effectively reduces these complications compared to either drug alone in children undergoing tonsillectomy and/or adenoidectomy with sevoflurane anesthesia. Patients and Methods: This randomized, double-blind trial involved 198 children aged 2− 5 years undergoing tonsillectomy and/or adenoidectomy. Participants received intranasal premedication with either dexmedetomidine (2 μg/kg), esketamine (1 mg/kg), or their combination (dexmedetomidine 1 μg/kg plus esketamine 0.5 mg/kg). The primary outcome was the incidence of emergence delirium, defined as a Pediatric Anesthesia Emergence Delirium (PAED) scale score ≥ 10. Secondary outcomes included the incidence of PNBC, sedation depth, easiness of separation from parents, acceptance of the mask for induction, emergence time, postoperative pain score, parental satisfaction, and adverse events. Results: The combination premedication significantly reduced emergence delirium incidence (9.4%) compared to esketamine alone (38.1%; relative risk [RR] 0.25, 95% confidence interval [CI] 0.11– 0.57, p < 0.001), but not compared to dexmedetomidine alone (17.2%; RR 0.55, 95% CI 0.21– 1.39, p = 0.193). PNBC incidence at day 7 was lower with the combination (28.1%) versus dexmedetomidine (48.4%; RR 0.58, 95% CI 0.36– 0.93, p = 0.018), but not significantly different from esketamine alone (20.6%; RR 1.38, 95% CI 0.74– 2.58, p = 0.326). The combination also provided significantly superior sedation, improved ease of separation from parents, better acceptance of the mask for induction, shorter emergence time, and higher parental satisfaction than both monotherapies. Conclusion: In children undergoing tonsillectomy and/or adenoidectomy with sevoflurane anesthesia, intranasal dexmedetomidine-esketamine premedication more effectively reduces emergence delirium compared to esketamine alone and PNBC compared to dexmedetomidine alone. This combination also improves sedation, shortens emergence times, and enhances parental satisfaction compared to monotherapy without significant adverse effects. Trial Registration: The Chinese Clinical Trial Registry, ChiCTR2300076709.

1 August 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
CXChenxia Xu
Chenxia Xu
GZGuanlin Zheng
Guanlin Zheng
YZYifen Zhuo
Yifen Zhuo
LHLinshan Huang
Linshan Huang
WGWeitao Gao
Weitao Gao
BQBin Qian
Bin Qian
Purpose: This study evaluated whether intranasal esketamine premedication reduces sevoflurane requirements for laryngeal mask airway (LMA) insertion in young children. Patients and Methods: This randomized, double-blind, placebo-controlled trial enrolled 90 children (2– 5 years) undergoing elective strabismus surgery. Participants received intranasal premedication with either saline (control), esketamine 0.5 mg/kg, or esketamine 1.0 mg/kg. The primary outcome was the minimum alveolar concentration of sevoflurane needed for successful LMA placement, determined using Dixon’s up-and-down method. Secondary outcomes included anesthesia induction quality (4-point cooperation scale), emergence delirium (Pediatric Anesthesia Emergence Delirium scale), emergence time (from sevoflurane discontinuation to purposeful response), behavioral changes at day 3 (Post-Hospitalization Behavior Questionnaire), and adverse events. Results: Intranasal esketamine produced dose-dependent reductions in sevoflurane requirements: 2.16 ± 0.18% (control), 1.87 ± 0.17% (0.5 mg/kg), and 1.50 ± 0.19% (1.0 mg/kg), representing decreases of 13.4% and 30.6%, respectively. The higher esketamine dose significantly improved induction quality (p=0.002), reduced emergence delirium (13.8% versus 46.4%, p=0.007), and decreased negative postoperative behavioral changes on day 3 (20.7% versus 53.6%, p=0.010). Emergence time and adverse event rates remained similar across groups. Conclusion: Intranasal esketamine premedication effectively reduces sevoflurane requirements for LMA placement in children in a dose-dependent manner. The 1.0 mg/kg dose provides optimal clinical benefits without prolonging recovery or increasing complications. This approach offers pediatric anesthesiologists a practical method to reduce volatile anesthetic exposure while improving patient outcomes and potentially minimizing anesthetic-related risks.

3 October 2026 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
YCYingjie Chen
Yingjie Chen
YTYanling Tang
Yanling Tang
YYYuwei Yang
Yuwei Yang
YHYongxin Huang
Yongxin Huang
DLDaoyi Lin
Daoyi Lin
YLYanling Liao
Yanling Liao
Sepsis heterogeneity remains a major barrier to precision medicine. Although cardio-renal-metabolic interactions critically influence outcomes, their dynam